Cardiovascular

Latest News

Effect of Remote Patient Monitoring on Stage 2 Hypertension
Effect of Remote Patient Monitoring on Stage 2 Hypertension

May 6th 2025

A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.

Q&A with Sid Patel, MD
Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

April 24th 2025

One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

April 18th 2025

Jeremy Wigginton, MD
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

April 8th 2025

ACC.25
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

April 4th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
May 7th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
May 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
May 7th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

stethoscope wrapped around globe
July 13th 2023

New Global Analysis Reveals Wide Variation in Lipid-Associated CVD Risk

Hayden E. Klein
Research was conducted by multiple laboratories in the Global Diagnostics Network and included more than 460 million lipid test results from 17 countries to determine risk of cardiovascular disease (CVD).
Non-Statin Therapies for Patients at High Risk for Cardiovascular Disease
March 31st 2023

Non-Statin Therapies for Patients at High Risk for Cardiovascular Disease

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.
Heart.
July 25th 2022

Risk of Myocardial Infarction Greater Among Patients With Hidradenitis Suppurativa

Matthew Gavidia
An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.
Treatment Disparities in the Management of ASCVD
May 31st 2022

Treatment Disparities in the Management of ASCVD

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.
Improving Patient and Provider Engagement
May 31st 2022

Improving Patient and Provider Engagement

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.
Utilizing Quality Metrics in ASCVD
May 31st 2022

Utilizing Quality Metrics in ASCVD

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.
Appropriate ASCVD Treatment Outside of Closed Health Systems
May 24th 2022

Appropriate ASCVD Treatment Outside of Closed Health Systems

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.
Improving Access to PCSK9 Inhibitors in the Inpatient Setting
May 24th 2022

Improving Access to PCSK9 Inhibitors in the Inpatient Setting

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.
Enhancing Patient Care Through Guideline Adherence
May 17th 2022

Enhancing Patient Care Through Guideline Adherence

Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.
The Future of LDL Management for Patients With High-Risk ASCVD
May 17th 2022

The Future of LDL Management for Patients With High-Risk ASCVD

Three cardiovascular experts discuss the future of lipid management for patients with high-risk ASCVD.
What Does a Multidisciplinary Team Look Like?
May 10th 2022

What Does a Multidisciplinary Team Look Like?

Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.
Defining “Optimal Care” for ASCVD Within Health Systems
May 10th 2022

Defining “Optimal Care” for ASCVD Within Health Systems

Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.
Unmet Needs in Lipid Management
May 3rd 2022

Unmet Needs in Lipid Management

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.
Ensuring Continuity of Care for the ASCVD Patient
May 3rd 2022

Ensuring Continuity of Care for the ASCVD Patient

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.
Using Adjunct Therapies in LDL Management
April 26th 2022

Using Adjunct Therapies in LDL Management

Dr Brinton highlights the importance of adjunct therapies in LDL management.
Therapy Beyond Statins in the Inpatient Setting
April 26th 2022

Therapy Beyond Statins in the Inpatient Setting

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.
Finding the Optimal Statin Dose
April 20th 2022

Finding the Optimal Statin Dose

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.
Who is an Ideal Patient for Early Intensive Lipid Lowering?
April 20th 2022

Who is an Ideal Patient for Early Intensive Lipid Lowering?

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.
Residual Cardiovascular Risk
April 8th 2022

Residual Cardiovascular Risk

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.
Improving the Care Continuum
April 8th 2022

Improving the Care Continuum

An expert advises how to optimize the care continuum for patients with ASCVD.
A Patient’s Post-MI Journey
April 8th 2022

A Patient’s Post-MI Journey

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.
The Burden of ASCVD and Evidence-Based Guidelines
April 8th 2022

The Burden of ASCVD and Evidence-Based Guidelines

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.
Heart cutout placed by stethoscope.
August 3rd 2021

Obstructive Sleep Apnea Linked With Accelerated Vascular Aging, CVD Risk

Matthew Gavidia
People with high risk of obstructive sleep apnea presented with significant changes in key arteries indicative of accelerated vascular aging, a known contributor to cardiovascular disease (CVD).
Site Logo
April 13th 2021

Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C–Lowering Therapies

Joanna P. MacEwan, PhD Lauren M. Zhao, BA Katie Everson, MS Larry Liu, MD, PhD Dominik Lautsch, PhD Fang Sun, MD, PhD Darius N. Lakdawalla, PhD
Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.
Site Logo
April 8th 2021

Clinical and Economic Outcomes of a Collaborative Cardiology Care Program

Felix Sebastian Wicke, MD, MSc Bianka Ditscheid, PhD Thorben Breitkreuz, MSc Anastasiya Glushan, BSc Thomas Lehmann, PhD Kateryna Karimova, PhD, MSc Olga Anastasia Sawicki, MD, MSc Monique Vogel, MD Antje Freytag, PhD Martin Beyer, MSc
Patients with chronic cardiac conditions benefited from a health care program that strengthened collaboration between general practitioners and cardiology specialists in Baden-Wuerttemberg, Germany.
Early Intervention in Younger Patients With CAD Benefits Long-Term Prognosis
December 31st 2020

Early Intervention in Younger Patients With CAD Benefits Long-Term Prognosis

Samantha DiGrande
Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.
Top 5 Most-Read Conference Stories of 2020
December 29th 2020

Top 5 Most-Read Conference Stories of 2020

Skylar Jeremias
The top 5 most-read conference stories of 2020 on AJMC.com included stories about study results on the impact that new therapies are having on cardiovascular and renal health.
Bleeding After DAPT Found to Be an Independent Predictor of Cardiovascular Events
December 28th 2020

Bleeding After DAPT Found to Be an Independent Predictor of Cardiovascular Events

Samantha DiGrande
A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.
ACC/AHA Clarify When AF Patients With Mitral Stenosis Should—And Should Not—Take DOACs
December 24th 2020

ACC/AHA Clarify When AF Patients With Mitral Stenosis Should—And Should Not—Take DOACs

Larry Hanover
The distinction between valvular and nonvalvular atrial fibrillation (AF) has been a persistent point of confusion for clinicians.
New ACC Pathway in Atrial Fibrillation Calls for Limiting Aspirin
December 22nd 2020

New ACC Pathway in Atrial Fibrillation Calls for Limiting Aspirin

Larry Hanover
The American College of Cardiology provides new guidance on the best therapy to prevent blood clots for patients with atherosclerotic cardiovascular disease who also have atrial fibrillation or venous thromboembolism and require an anticoagulant.
<12345678910
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo